{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:44:43Z","timestamp":1791233083462,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018740","name":"Anna-Greta Crafoord Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018740","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["SLS-784201"],"award-info":[{"award-number":["SLS-784201"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"crossref","award":["R-742291"],"award-info":[{"award-number":["R-742291"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Stiftelsen Ulla och Roland Gustafssons Donationsfond"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Mycophenolate mofetil (MMF) is an established therapy for systemic sclerosis (SSc), but its pharmacokinetics in this disease remains unexplored. We have investigated drug exposure in MMF-treated patients with SSc in relation to clinical features of the disease and common concomitant drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was predefined to include 35 MMF-treated SSc patients who were using MMF at a fixed dose of 0.5, 1.0 or 1.5\u2009g twice daily since at least 3\u2009months. The 12-h drug exposure of the active MMF metabolite mycophenolic acid (MPA) was estimated by repeated analysis of plasma MPA over a 6-h period. This 12-h drug exposure was dose normalised to a daily intake of 3\u2009g MMF (MPA_AUC<jats:sub>3g<\/jats:sub>) in order to compare subjects using MMF at different doses. Drug exposure was analysed in reference to the clinical characteristics including body weight, renal function, autoantibodies, intestinal dysbiosis, intestinal inflammation assessed by faecal (F)-calprotectin, intestinal symptoms assessed by the University of California Los Angeles Scleroderma Trial Consortium Gastrointestinal Tract Instrument 2.0 and concomitant drug usage including proton-pump inhibitors (PPI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty-four out of 35 study participants completed the study. The mean daily MMF dose was 2.1\u2009g. Drug exposure expressed as MPA_AUC<jats:sub>3g<\/jats:sub>varied up to 8-fold between patients (median 115, range 27\u2013226\u2009mg\u00a0h\/L).<\/jats:p><jats:p>MPA_AUC<jats:sub>3g<\/jats:sub>was inversely related to body weight (<jats:italic>r<\/jats:italic><jats:sub><jats:italic>s<\/jats:italic><\/jats:sub>\u2009=\u2009\u2212\u20090.58,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and renal function (<jats:italic>r<\/jats:italic><jats:sub><jats:italic>s<\/jats:italic><\/jats:sub>\u2009=\u2009\u2212\u20090.34,<jats:italic>p<\/jats:italic>\u2009=\u20090.054). Anti-topoisomerase-1 antibodies and male sex were associated with lower MPA_AUC<jats:sub>3g<\/jats:sub>(87 vs 123 and 71 vs 141;<jats:italic>p<\/jats:italic>\u2009=\u20090.008 and<jats:italic>p<\/jats:italic>\u2009=\u20090.015, respectively). MPA_AUC<jats:sub>3g<\/jats:sub>was inversely related to the intestinal abundance of lactobacilli and to F-calprotectin (<jats:italic>r<\/jats:italic><jats:sub><jats:italic>s<\/jats:italic><\/jats:sub>\u2009=\u2009\u2212\u20090.54,<jats:italic>p<\/jats:italic>\u2009=\u20090.004;<jats:italic>r<\/jats:italic><jats:sub><jats:italic>s<\/jats:italic><\/jats:sub>\u2009=\u2009\u2212\u20090.36,<jats:italic>p<\/jats:italic>\u2009=\u20090.034), but not to gastrointestinal symptoms. MPA_AUC<jats:sub>3g<\/jats:sub>was inversely related to PPI usage (<jats:italic>r<\/jats:italic><jats:sub><jats:italic>s<\/jats:italic><\/jats:sub>\u2009=\u2009\u2212\u20090.45,<jats:italic>p<\/jats:italic>\u2009=\u20090.007). We found no association between MPA_AUC<jats:sub>3g<\/jats:sub>and disease subtype, disease duration or disease activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MMF-treated SSc patients exhibit considerable inter-individual variation in drug exposure, and lower MPA levels were primarily found in PPI users with poor prognostic factors. Body weight, renal function, sex, serology, gastrointestinal manifestations and\/or measuring individual MPA exposure should be considered when using MMF for SSc.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13075-020-02323-8","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T19:02:54Z","timestamp":1602010974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation\u2014a prospective, observational study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-2541","authenticated-orcid":false,"given":"Kristofer","family":"Andr\u00e9asson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Neringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk M.","family":"Wuttge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Henrohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Marsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hesselstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"issue":"8961","key":"2323_CR1","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","volume":"345","author":"European Mycophenolate Mofetil Cooperative Study Group","year":"1995","unstructured":"European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995;345(8961):1321\u20135.","journal-title":"Lancet."},{"issue":"9","key":"2323_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708\u201319.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"2323_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/art.40114","volume":"69","author":"ER Volkmann","year":"2017","unstructured":"Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 2017;69(7):1451\u201360.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"2323_CR4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","volume":"76","author":"AL Herrick","year":"2017","unstructured":"Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017;76(7):1207\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2323_CR5","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70(11):1820\u20138.","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"2323_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","volume":"28","author":"T van Gelder","year":"2006","unstructured":"van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28(2):145\u201354.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"2323_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/jcph.1565","volume":"60","author":"J Benjanuwattra","year":"2020","unstructured":"Benjanuwattra J, Pruksakorn D, Koonrungsesomboon N. Mycophenolic acid and its pharmacokinetic drug-drug interactions in humans: review of the evidence and clinical implications. J Clin Pharmacol. 2020;60(3):295\u2013311.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2323_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/FTD.0b013e3181a23f1a","volume":"31","author":"BC de Winter","year":"2009","unstructured":"de Winter BC, Neumann I, van Hest RM, van Gelder T, Mathot RA. Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease. Ther Drug Monit. 2009;31(3):382\u201390.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"2323_CR9","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/art.27495","volume":"62","author":"N Zahr","year":"2010","unstructured":"Zahr N, Arnaud L, Marquet P, Haroche J, Costedoat-Chalumeau N, Hulot JS. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum. 2010;62(7):2047\u201354.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2323_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12185-011-0888-6","volume":"94","author":"K Wakahashi","year":"2011","unstructured":"Wakahashi K, Yamamori M, Minagawa K, Ishii S, Nishikawa S, Shimoyama M, et al. Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation. Int J Hematol. 2011;94(2):193\u2013202.","journal-title":"Int J Hematol"},{"issue":"1","key":"2323_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2796.2010.02340.x","volume":"270","author":"K Andr\u00e9asson","year":"2011","unstructured":"Andr\u00e9asson K, Scheja A, Saxne T, Ohlsson B, Hesselstrand R. Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis. J Intern Med. 2011;270(1):50\u20137.","journal-title":"J Intern Med"},{"issue":"1","key":"2323_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13075-016-1182-z","volume":"18","author":"K Andr\u00e9asson","year":"2016","unstructured":"Andr\u00e9asson K, Alrawi Z, Persson A, J\u00f6nsson G, Marsal J. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease. Arthritis Res Ther. 2016;18(1):278.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"2323_CR13","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/art.39572","volume":"68","author":"ER Volkmann","year":"2016","unstructured":"Volkmann ER, Chang YL, Barroso N, Furst DE, Clements PJ, Gorn AH, et al. Association of systemic sclerosis with a unique colonic microbial consortium. Arthritis Rheumatol. 2016;68(6):1483\u201392.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"2323_CR14","doi-asserted-by":"publisher","first-page":"14874","DOI":"10.1038\/s41598-017-14889-6","volume":"7","author":"V Patrone","year":"2017","unstructured":"Patrone V, Puglisi E, Cardinali M, Schnitzler TS, Svegliati S, Festa A, et al. Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement. Sci Rep. 2017;7(1):14874.","journal-title":"Sci Rep"},{"issue":"4","key":"2323_CR15","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/rheumatology\/key350","volume":"58","author":"N Richard","year":"2019","unstructured":"Richard N, Hudson M, Wang M, Gyger G, Proudman S, Stevens W, et al. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. Rheumatology (Oxford). 2019;58(4):636\u201344.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2323_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/03009748709102917","volume":"16","author":"T Ammitzb\u00f8ll","year":"1987","unstructured":"Ammitzb\u00f8ll T, Hendel L, Kreuzig F, Asboe-Hansen G. Bioavailability of D-penicillamine in relation to gastrointestinal involvement of generalized scleroderma. Scand J Rheumatol. 1987;16(2):121\u20136.","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"2323_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.semarthrit.2019.06.012","volume":"50","author":"FA Mendoza","year":"2020","unstructured":"Mendoza FA, Lee-Ching C, Jimenez SA. Recurrence of progressive skin involvement following discontinuation or dose reduction of mycophenolate mofetil treatment in patients with diffuse systemic sclerosis. Semin Arthritis Rheum. 2020;50(1):135\u20139.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2323_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1124\/jpet.106.117051","volume":"321","author":"N Roos","year":"2007","unstructured":"Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther. 2007;321(2):583\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"2323_CR19","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737\u201347.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2323_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00228-012-1323-5","volume":"69","author":"AM Sandqvist","year":"2013","unstructured":"Sandqvist AM, Henrohn D, Schneede J, Hedeland M, Eger\u00f6d HC, Bondesson UG, et al. High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. Eur J Clin Pharmacol. 2013;69(2):197\u2013207.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2323_CR21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirj\u00e1k L, Farge-Bancel D, Kowal-Bielecka O, M\u00fcller-Ladner U, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66(6):754\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2323_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/00365511003642535","volume":"70","author":"A Grubb","year":"2010","unstructured":"Grubb A. Non-invasive estimation of glomerular filtration rate (GFR). The Lund model: simultaneous use of cystatin C- and creatinine-based GFR-prediction equations, clinical data and an internal quality check. Scand J Clin Lab Invest. 2010;70(2):65\u201370.","journal-title":"Scand J Clin Lab Invest"},{"issue":"9","key":"2323_CR23","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/art.24730","volume":"61","author":"D Khanna","year":"2009","unstructured":"Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum. 2009;61(9):1257\u201363.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2323_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","volume":"76","author":"G Valentini","year":"2017","unstructured":"Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017;76(1):270\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2323_CR25","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.3899\/jrheum.090694","volume":"36","author":"M Baron","year":"2009","unstructured":"Baron M, Hudson M, Steele R, Canadian Scleroderma Research Group. Malnutrition is common in systemic sclerosis: results from the Canadian Scleroderma Research Group database. J Rheumatol. 2009;36(12):2737\u201343.","journal-title":"J Rheumatol"},{"issue":"3","key":"2323_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00228-018-2599-x","volume":"75","author":"P Luszczy\u0144ska","year":"2019","unstructured":"Luszczy\u0144ska P, Pawi\u0144ski T, Kunicki PK, Durlik M, Augustyniak-Bartosik H, Hurkacz M. Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring. Eur J Clin Pharmacol. 2019;75(3):371\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"2323_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/cei.12246","volume":"176","author":"B Chaigne","year":"2014","unstructured":"Chaigne B, Gatault P, Darrouzain F, Barbet C, Degenne D, Fran\u00e7ois M, et al. Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study. Clin Exp Immunol. 2014;176(2):172\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"2323_CR28","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3109\/0886022X.2015.1010442","volume":"37","author":"RM Veli\u010dkovi\u0107-Radovanovi\u0107","year":"2015","unstructured":"Veli\u010dkovi\u0107-Radovanovi\u0107 RM, Jankovi\u0107 SM, Milovanovi\u0107 JR, Cati\u0107-Dordevi\u0107 AK, Spasi\u0107 AS, Stefanovi\u0107 NZ, et al. Variability of mycophenolic acid elimination in the renal transplant recipients \u2013 population pharmacokinetic approach. Ren Fail. 2015;37(4):652\u20138.","journal-title":"Ren Fail"},{"issue":"6","key":"2323_CR29","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/art.38390","volume":"66","author":"SI Nihtyanova","year":"2014","unstructured":"Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014;66(6):1625\u201335.","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"2323_CR30","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1093\/rheumatology\/keq238","volume":"49","author":"M Schaier","year":"2010","unstructured":"Schaier M, Scholl C, Scharpf D, Hug F, B\u00f6nisch-Schmidt S, Dikow R, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford). 2010;49(11):2061\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 17","key":"2323_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1399-0012.2006.00597.x","volume":"20","author":"C Morath","year":"2006","unstructured":"Morath C, Schwenger V, Beimler J, Mehrabi A, Schmidt J, Zeier M, et al. Antifibrotic actions of mycophenolic acid. Clin Transpl. 2006;20(Suppl 17):25\u20139.","journal-title":"Clin Transpl"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02323-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T09:32:18Z","timestamp":1698226338000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02323-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2323"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02323-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"17 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Swedish Ethical Review Authority (Dnr 2018\/490) and the Swedish Medical Products Agency (EudraCT 2018-002105-54) and prospectively registered at(NCT03678987, posted September 20, 2018). All participants gave their written informed consent prior to entering the study. The study was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}